StreetInsider.com News Articles

Form 8-K Sonoma Pharmaceuticals, For: Aug 19

Wed, 19 Aug 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260819/26951235.html

Form 8-K Sonoma Pharmaceuticals, For: Aug 19

Wed, 19 Aug 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260819/26951235.html

Sonoma Pharmaceuticals (SNOA) Tops Q1 EPS by 21c

Thu, 06 Aug 2026 09:20:21 -0400

Sonoma Pharmaceuticals (NASDAQ: SNOA) reported Q1 EPS of ($0.09), $0.21 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $6.4 million versus the consensus estimate of $4.99 million.

For earnings history and earnings-related data on Sonoma Pharmaceuticals (SNOA) click here.

Sonoma Pharmaceuticals posts 60% revenue rise, first positive EBITDA

Thu, 06 Aug 2026 09:01:47 -0400

Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) reported total revenues of $6.4 million for its fiscal first quarter ended June 30, 2026, a 60% increase from $4.0 million in the same period a year earlier, according to a company press release.

U.S. revenue rose 141%, or $1.4 million, driven by over-the-counter product sales and growth from new and existing distributors. European revenue increased 34%, or $0.5 million, attributed to higher demand and favorable exchange rates.

Gross profit reached $2.6 million, or 40% of revenue, compared to $1.5 million, or 36%, in the prior-year quarter. Total operating expenses were $2.6 million in both periods. The

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Thu, 06 Aug 2026 09:00:00 -0400

Total revenue increased 60% year over year to $6.4 million
Net loss per share decreased 88% compared to the prior-year quarter
Gross margin expanded to 40% as operating expenses remained stable
FDA clearance and new global distributors support continued commercial growth

BOULDER, CO / ACCESS Newswire / August 6, 2026 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn^® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications including wound care, eye care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants, today announced financial results

Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA

Thu, 06 Aug 2026 09:00:00 -0400

Total revenue increased 60% year over year to $6.4 million
Net loss per share decreased 88% compared to the prior-year quarter
Gross margin expanded to 40% as operating expenses remained stable
FDA clearance and new global distributors support continued commercial growth

Form 10-Q Sonoma Pharmaceuticals, For: Jun 30

Thu, 06 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26879767.html

Form 10-Q Sonoma Pharmaceuticals, For: Jun 30

Thu, 06 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260806/26879767.html

Form DEF 14A Sonoma Pharmaceuticals, For: Sep 16

Tue, 28 Jul 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260728/26828073.html

Form DEF 14A Sonoma Pharmaceuticals, For: Sep 16

Tue, 28 Jul 2026 16:50:00 -0400

si-local-file:///var/storage/secattach/20260728/26828073.html

Form DEFA14A Sonoma Pharmaceuticals,

Thu, 23 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260723/26803726.html

Form DEFA14A Sonoma Pharmaceuticals,

Thu, 23 Jul 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260723/26803726.html

Form 4 Sonoma Pharmaceuticals, For: Jul 09 Filed by: Trombly Amy Moss

Thu, 09 Jul 2026 20:48:00 -0400

si-local-file:///var/storage/secattach/20260709/26754199.html

Form 4 Sonoma Pharmaceuticals, For: Jul 09 Filed by: Trombly Amy Moss

Thu, 09 Jul 2026 20:48:00 -0400

si-local-file:///var/storage/secattach/20260709/26754199.html

Form 4 Sonoma Pharmaceuticals, For: Jul 09 Filed by: Weigerstorfer Philippe

Thu, 09 Jul 2026 20:48:00 -0400

si-local-file:///var/storage/secattach/20260709/26754200.html

Form 4 Sonoma Pharmaceuticals, For: Jul 09 Filed by: Weigerstorfer Philippe

Thu, 09 Jul 2026 20:48:00 -0400

si-local-file:///var/storage/secattach/20260709/26754200.html

Form 4 Sonoma Pharmaceuticals, For: Jul 09 Filed by: Dal Poggetto John